
    
      1. Patient (1) Inclusion: Diagnosed as gastric dysplasia or early gastric cancer

             -  Scheduled for ESD (2) Exclusion: Coagulopathy- liver cirrhosis, thrombocytopenia

             -  Anti-platelet agents

        2. Method

      (1) Study group: combination with SurgicelÂ® Fibrillar and H2RA (2) Control group: monotherapy
      with PPI 3. Sample size : 157 4. Result

        1. Primary endpoint: rate of delayed bleeding after ESD

        2. Secondary endpoint: follow-up hemoglobin after ESD
    
  